Built for de-risking decisions at any stage

Before a dollar is spent or a trial begins, the Derisq™ AI Report by GATC Health gives executives a validated read on drug safety, efficacy, and risk – becoming biotech’s FICO® score for smarter, faster, and more defensible decisions.

Request a Consultation

Explore Platform Capabilities:

https://gatc.parkandbattery.com/wp-content/uploads/2025/10/ai-report-derisq-bg.png

The definitive AI report for predictive risk intelligence

Drug development demands high-stakes decisions long before clinical data is available. The Derisq AI Report by GATC Health gives biotech leaders and investors the power to prioritize their pipeline, define optimal clinical trial criteria, and uncover risks that might otherwise go unseen.

The Derisq report’s underlying technology has been independently verified by the University of California, Irvine – showing approximately 90% accuracy in predicting drug candidate outcomes – making it a trusted resource for insurance underwriters and investors alike.

Clarity before clinical trial

Built on GATC Health’s proprietary Operon™ AI engine, the Derisq Report does exactly what it says: it de-risks decision-making anywhere in the development timeline by predicting safety, efficacy, and off-target effects with validated accuracy.

Learn More about Operon

87%

Predictive Accuracy

Outperforms industry average by 20x in early-stage drug success predictions

10-18

months

to progress through pre-clinical

How it works

Enable smarter trial design

The Derisq AI report helps teams design efficient, targeted trials – reducing timelines, optimizing endpoints, and increasing the odds of drug candidate success.

Reduce investor risk

The Derisq report provides clear, data-backed insights to de-risk important decisions, validate your science early, and strengthen investor confidence.

Maximize capital efficiency

Focus resources on high-potential assets, avoid unnecessary spend, and strategically manage burn by leveraging the Derisq AI Report, enabling better early-stage decision-making.

Elevate strategic planning

Strengthen board and shareholder trust with the Derisq report, offering transparent and data-driven assessments that align pipeline strategy with measurable value.

Find clarity at critical moments

The Derisq AI Report provides biotech leaders and investors with a comprehensive, objective assessment of a drug candidate’s likely clinical trial performance, with modules including, but not limited to:

Safety

& toxicology

Adverse events (AE), side effects, bioaccumulation

Pharmacokinetics

& ADME

Absorption, metabolism, immunogenicity

Efficacy &

mechanism of action

Target validation, endpoint selection

Contact us

You know the impact your breakthrough could have on the world – it’s getting there that’s the challenge. What if you could reach clinical trial with a greater understanding of the full potential risks and efficacy of each drug candidate, so that you could pre-select and find certainty and success? It’s possible with our predictive AI-powered platform.

"*" indicates required fields